• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    9/20/23 2:10:56 PM ET
    $ADD
    $AGRI
    $ASST
    $ATRA
    Engineering & Construction
    Consumer Discretionary
    Metal Fabrications
    Industrials
    Get the next $ADD alert in real time by email

    Gainers

    MSP Recovery, Inc. (NASDAQ:LIFW) shares jumped 104.5% to $0.1916.

    Digital Transformation Opportunities Corp. (NASDAQ:DTOC) rose 100.7% to $27.50 after dipping 53% on Tuesday.

    Bluejay Diagnostics, Inc. (NASDAQ:BJDX) gained 56.4% to $4.8499. Bluejay Diagnostics, last month, announced a $1.59 million registered direct offering of 216,000 shares at $7.365 per share.

    Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) shares gained 50% to $0.8705 after the company announced its Board of Directors has approved a plan of liquidation and dissolution.

    AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) rose 38% to $0.1478.

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares gained 32.9% to $0.6974 after falling 10% on Tuesday.

    Evaxion Biotech A/S (NASDAQ:EVAX) gained 29.2% to $0.6201. Evaxion partnered with pharmaceutical company Afrigen Biologics to develop novel mRNA vaccine against gonorrhoea.

    Steelcase Inc. (NYSE:SCS) jumped 27.3% to $11.22. Steelcase reported better-than-expected results for its second quarter.

    Solowin Holdings (NASDAQ:SWIN) gained 26% to $3.08.

    Cambridge Bancorp (NASDAQ:CATC) rose 23.9% to $60.22 after the company announced it entered into a definitive agreement to merge with Eastern Bankshares.

    Histogen Inc. (NASDAQ:HSTO) shares rose 23.4% to $0.4873. Histogen shares fell 40% on Tuesday after the company announced its Board of Directors approved a Plan of Dissolution.

    Genius Group Limited (NYSE:GNS) jumped 22.2% to $1.0750. Genius Group signed a joint venture partnership with Groove Digital Inc and Groove AI to deliver artificial-intelligence powered tools to GeniusU partners and faculty.

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) gained 22% to $0.3047.

    eHealth, Inc. (NASDAQ:EHTH) gained 20.1% to $8.07. eHealth Form 4 filing showed Director Dale B Wolf bought 15,000 shares at an average price of $7.05.

    Asset Entities Inc. (NASDAQ:ASST) jumped 19.4% to $0.64.

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rose 17.7% to $1.8606. Atara Biotherapeutics announced plans to submit Tab-cel BLA in the second quarter of 2024 following FDA agreement on comparability.

    EBET, Inc. (NASDAQ:EBET) shares gained 16.7% to $0.0618.

    Azul S.A. (NYSE:AZUL) jumped 12.8% to $9.33. Goldman Sachs upgraded Azul from Neutral to Buy and raised the price target from $14.9 to $18.3.

    The Hain Celestial Group, Inc. (NASDAQ:HAIN) jumped 9% to $10.60.

    Gol Linhas Aéreas Inteligentes S.A. (NYSE:GOL) gained 8.3% to $2.9350 as the company disclosed preliminary traffic figures for August.

    Losers

    Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares fell 75.2% to $0.2477 after the company announced its SLS-002 Phase II study did not meet the pre-defined primary endpoint due to limited sample size.

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) fell 55.1% to $2.9650. The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals’ New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for adults and children ≥30 kg.

    Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares fell 40% to $0.1181 after jumping 160% on Tuesday.

    Molekule Group, Inc. (NASDAQ:MKUL) fell 37.6% to $0.4589. Molekule Group said board authorized the company’s management to commence preparation of voluntary petition under Chapter 11 of the U.S. Bankruptcy Code.

    IceCure Medical Ltd (NASDAQ:ICCM) fell 36.6% to $0.57 after the company announced the FDA has at this time denied its De Novo Classification request for breast cancer which was submitted based on interim analysis from its ICE3 study.

    QuantaSing Group Limited (NASDAQ:QSG) declined 36.4% to $3.47.

    Bird Global, Inc. (NYSE:BRDS) shares fell 32.2% to $0.97. Bird Global shares jumped more than 103% on Tuesday after the company announced its purchase of micromobility operator Skinny Labs for $19 million.

    Gorilla Technology Group Inc. (NASDAQ:GRRR) declined 24.6% to $1.07. Gorilla announced a $25 million registered direct offering of convertible preferred stock.

    Cheche Group Inc. (NASDAQ:CCG) shares fell 22.8% to $25.00 after falling 56% on Tuesday.

    Elutia Inc. (NASDAQ:ELUT) fell 18.8% to $1.34 after jumping 33% on Tuesday. The company announced a $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.

    Cazoo Group Ltd (NYSE:CZOO) declined 16.9% to $0.8227. Cazoo announced deleveraging plan with noteholders and shareholders, enhancing financial flexibility.

    Axcella Health Inc. (NASDAQ:AXLA) declined 16.6% to $10.13. The company recently announced 1-for-25 reverse stock split.

    TD Holdings, Inc. (NASDAQ:GLG) fell 12.6% to $0.1510 after gaining 7% on Tuesday.

    CSP Inc. (NASDAQ:CSPI) fell 12.6% to $17.13.

    Calidi Biotherapeutics, Inc. (NASDAQ:CLDI) fell 10.1% to $3.04.

    ImmunityBio, Inc. (NASDAQ:IBRX) tumbled 9.2% to $1.6250.

    Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares fell 8% to $11.02.

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) fell 7.4% to $9.97.

    BeiGene, Ltd. (NASDAQ:BGNE) fell 7.2% to $193.86. B of A Securities analyst David Li maintained BeiGene with a Neutral and lowered the price target from $224.13 to $212.

    Color Star Technology Co., Ltd. (NASDAQ:ADD) declined 7% to $1.4599.

    Now Read This: Top 4 Financial Stocks That May Fall Off A Cliff

    Get the next $ADD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADD
    $AGRI
    $ASST
    $ATRA

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Neumora Therapeutics Inc.
    $NMRA
    2/17/2026Mkt Perform → Outperform
    William Blair
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Gorilla Technology Group Inc.
    $GRRR
    12/11/2025$31.00Overweight
    Cantor Fitzgerald
    Orchestra BioMed Holdings Inc.
    $OBIO
    12/10/2025$15.00Buy
    TD Cowen
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    ARS Pharmaceuticals Inc.
    $SPRY
    11/4/2025$30.00Buy
    Roth Capital
    More analyst ratings

    $ADD
    $AGRI
    $ASST
    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:07:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Pinto Joshua sold $21,093 worth of shares (5,967 units at $3.54), decreasing direct ownership by 9% to 57,783 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:06:16 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Berns Paul L sold $34,459 worth of shares (9,819 units at $3.51), decreasing direct ownership by 0.13% to 7,395,185 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:05:16 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADD
    $AGRI
    $ASST
    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by William Blair

    William Blair upgraded Neumora Therapeutics from Mkt Perform to Outperform

    2/17/26 7:22:19 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADD
    $AGRI
    $ASST
    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Nerges Joseph R bought $101,525 worth of shares (11,012 units at $9.22), increasing direct ownership by 0.79% to 1,406,075 units (SEC Form 4)

    4 - CSP INC /MA/ (0000356037) (Issuer)

    2/19/26 1:48:39 PM ET
    $CSPI
    EDP Services
    Technology

    Chief Financial Officer Pham Benjamin bought $115,095 worth of shares (14,114 units at $8.15) (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/19/26 8:00:23 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Chief Legal Officer Beirne Brian Logan bought $100,387 worth of shares (11,500 units at $8.73), increasing direct ownership by 310% to 15,204 units (SEC Form 4)

    4 - Strive, Inc. (0001920406) (Issuer)

    2/17/26 8:02:53 AM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    $ADD
    $AGRI
    $ASST
    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

    Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and healthcare systems throughout the MENA region The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA ANKTIVA will be available for distribution within the next 60 days Initiated discussion with Saudi FDA and UAE regulatory authorities to expand ANKTIVA indications beyond Lung and Bladder cancers ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced a part

    2/20/26 8:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

    SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company's website. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloa

    2/20/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

    ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share. The Company notes that several recent Schedule 13G filings made by investors

    2/20/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADD
    $AGRI
    $ASST
    $ATRA
    SEC Filings

    View All

    SEC Form FWP filed by Strive Inc.

    FWP - Strive, Inc. (0001920406) (Subject)

    2/20/26 5:24:32 PM ET
    $ASST
    Computer Software: Prepackaged Software
    Technology

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    2/20/26 9:54:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Genius Group Limited

    6-K - Genius Group Ltd (0001847806) (Filer)

    2/19/26 8:01:44 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ADD
    $AGRI
    $ASST
    $ATRA
    Leadership Updates

    Live Leadership Updates

    View All

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADD
    $AGRI
    $ASST
    $ATRA
    Financials

    Live finance-specific insights

    View All

    Gorilla Technology Acquires Shackleton Finance to Establish Regulated Capital Platform and Fund AI Infrastructure Growth

    - Newly formed entity, Gorilla Technology Capital, will support expansion and capital formation for large-scale AI data centres and mission-critical digital infrastructure -London, United Kingdom--(Newsfile Corp. - February 18, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence, IoT technology and data centres, today announced that it has entered into a memorandum of understanding outlining the principal terms of a proposed acquisition of Shackleton Finance Limited ("Shackleton"), a UK-authorised Alternative Investment Fund Manager (AIFM) and subsidiary of Shackleto

    2/18/26 9:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Diamond Equity Research Releases Update Note on Genius Group Ltd. (NYSE: GNS)

    New York, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on Genius Group Ltd. (NYSE:GNS). The update note includes information on the Genius Group Ltd.' financial results, management commentary, recent developments, outlook, and risks. The research summary below is from a report commissioned by Genius Group Ltd. and produced by Diamond Equity Research. Investors can find various risk factors in the update report and in the respective financial filings for Genius Group Limited.  The full research report is available below. Genius Group February 2026 Update Note  Highlight

    2/17/26 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    eHealth, Inc. to Hold Fourth Quarter and Fiscal Year 2025 Earnings Call on February 25 at 5:00 p.m. Eastern Time

    AUSTIN, Texas, Feb. 9, 2026 /PRNewswire/ -- eHealth, Inc. (NASDAQ:EHTH), a leading private online health insurance marketplace, today announced that the company plans to release fourth quarter and fiscal year 2025 financial results on February 25, 2026. The company will hold an earnings conference call beginning at 5:00 p.m. Eastern Time on February 25th to discuss these results. The call will be hosted by eHealth's chief executive officer, Derrick Duke, and eHealth's chief financial officer, John Dolan. Individuals interested in listening to the conference call may do so by dialing (800) 549-8228. The participant passcode is 52426. A live webcast of the earnings call will be available under

    2/9/26 5:50:00 PM ET
    $EHTH
    Specialty Insurers
    Finance

    $ADD
    $AGRI
    $ASST
    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology